首页 > 最新文献

Diseases (Basel, Switzerland)最新文献

英文 中文
The COVID-19 Pandemic and Emergencies in Otolaryngology-Head and Neck Surgery: An Analysis of Patients Presenting to Emergency Rooms in South-West Germany: A Bi-Center Study. COVID-19 大流行与耳鼻咽喉头颈外科急诊:德国西南部急诊室就诊患者分析:一项双中心研究。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-22 DOI: 10.3390/diseases12080194
Stephan Wolpert, Nora Knoblich, Martin Holderried, Sven Becker, Thore Schade-Mann

This study was designed to examine the changes in emergency room visits in otolaryngology, head and neck surgery, during the COVID-19 pandemic. The study included 11,277 patients who presented to a tertiary care hospital (ER) and an emergency practice (EP) during on-call hours in the first half of 2018, 2019, and 2020. The epidemiologic parameters, diagnoses, and level of urgency were recorded using a four-step scale. A comparison was made between the pre-pandemic years and 2020. The findings revealed a significant decrease in the frequency of ER visits in the second quarter of 2020 compared to 2019 (ER: 30.8%, EP: 37.8%), mainly due to the fact that there were significantly fewer patients, with low levels of urgency. Certain diagnoses, such as epistaxis (-3.0%) and globus sensation (-3.2%), were made at similar frequencies to 2019, while inflammatory diseases like skin infections (-51.2%), tonsillitis (-55.6%), sinusitis (-59%), and otitis media (-70.4%) showed a significant reduction. The study concludes that patients with a low triage level were less likely to visit the ER during the early stages of the pandemic, but some diagnoses were still observed at comparable rates. This suggests a disparity in perception between patients and ER staff regarding urgency. Many of the issues discussed were also emphasized in the 2024 proposal by the German Ministry of Health to reform emergency care in Germany.

本研究旨在探讨 COVID-19 大流行期间耳鼻咽喉头颈外科急诊就诊人数的变化。研究纳入了 2018 年、2019 年和 2020 年上半年在值班时间内到三级医院(ER)和急诊诊所(EP)就诊的 11277 名患者。采用四级量表记录了流行病学参数、诊断和紧急程度。对流行前几年和 2020 年进行了比较。研究结果显示,与 2019 年相比,2020 年第二季度急诊室就诊频率明显下降(急诊室:30.8%,急诊室:37.8%),这主要是由于急诊程度低的患者人数明显减少。某些诊断,如鼻衄(-3.0%)和球状感觉(-3.2%)的频率与 2019 年相似,而炎症性疾病,如皮肤感染(-51.2%)、扁桃体炎(-55.6%)、鼻窦炎(-59%)和中耳炎(-70.4%)则显著减少。研究得出结论,在流感大流行的早期阶段,分流级别较低的患者到急诊室就诊的可能性较小,但某些诊断的就诊率仍然相当。这表明患者和急诊室工作人员对紧急程度的认识存在差异。德国卫生部在 2024 年提出的德国急诊改革方案中也强调了许多讨论过的问题。
{"title":"The COVID-19 Pandemic and Emergencies in Otolaryngology-Head and Neck Surgery: An Analysis of Patients Presenting to Emergency Rooms in South-West Germany: A Bi-Center Study.","authors":"Stephan Wolpert, Nora Knoblich, Martin Holderried, Sven Becker, Thore Schade-Mann","doi":"10.3390/diseases12080194","DOIUrl":"10.3390/diseases12080194","url":null,"abstract":"<p><p>This study was designed to examine the changes in emergency room visits in otolaryngology, head and neck surgery, during the COVID-19 pandemic. The study included 11,277 patients who presented to a tertiary care hospital (ER) and an emergency practice (EP) during on-call hours in the first half of 2018, 2019, and 2020. The epidemiologic parameters, diagnoses, and level of urgency were recorded using a four-step scale. A comparison was made between the pre-pandemic years and 2020. The findings revealed a significant decrease in the frequency of ER visits in the second quarter of 2020 compared to 2019 (ER: 30.8%, EP: 37.8%), mainly due to the fact that there were significantly fewer patients, with low levels of urgency. Certain diagnoses, such as epistaxis (-3.0%) and globus sensation (-3.2%), were made at similar frequencies to 2019, while inflammatory diseases like skin infections (-51.2%), tonsillitis (-55.6%), sinusitis (-59%), and otitis media (-70.4%) showed a significant reduction. The study concludes that patients with a low triage level were less likely to visit the ER during the early stages of the pandemic, but some diagnoses were still observed at comparable rates. This suggests a disparity in perception between patients and ER staff regarding urgency. Many of the issues discussed were also emphasized in the 2024 proposal by the German Ministry of Health to reform emergency care in Germany.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of an Acupuncture Steam-Warming Eye Mask on Dry Eye Disease in Visual Display Terminal Users: A Prospective Randomized Controlled Trial. 针灸蒸汽温热眼罩对视觉显示终端使用者干眼症的疗效:前瞻性随机对照试验。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-22 DOI: 10.3390/diseases12080192
Chia-Yi Lee, Shun-Fa Yang, Ching-Hsi Hsiao, Chi-Chin Sun, Chao-Kai Chang, Jing-Yang Huang, Yih-Shiou Hwang

We aim to evaluate the effectiveness of an acupuncture steam-warming eye mask (ASEM) on dry eye disease (DED) in visual display terminal (VDT) users. This prospective randomized clinical trial included VDT users with DED-related features who were randomly assigned to the ASEM group (ASEM for 2 weeks, 20 participants) or the steam-warming eye mask (SEM) group (SEM for 2 weeks, 20 participants). The tear film break-up time (TBUT), Schirmer test, tear meniscus height, ocular surface staining scores, eyelid and meibomian gland exam, subjective symptoms, and quality of life (QoL) scores before and after treatment were collected. A generalized linear mixed model was applied to compare the improvement of symptoms and signs between the two groups. After the 2-week treatment, all the subjective symptoms and questionnaire scores in the ASEM group improved significantly (all p < 0.05), whereas the feelings of relaxation, comfortable, and refreshment did not change in the SEM group (both p > 0.05). The TBUT, tear meniscus height, and meibum quality in the lower eyelid were significantly better in the ASEM group than the SEM group (all p < 0.05), whereas no significant changes were observed in the Schirmer test and ocular surface staining scores. Compared with the SEM group, the ASEM group experienced a stronger feeling of refreshment (p = 0.013), lower sensation of ocular discharge (p = 0.031), higher TBUT (p = 0.045), better meibomian gland expressibility of both eyelids (both p < 0.05), and better meibum quality of both eyelids (both p < 0.05), even after adjustments for age and sex. In conclusion, comparing with SEM, ASEM can improve some subjective DED symptoms, tear film stability, and meibum status in VDT users.

我们旨在评估针灸蒸汽温热眼罩(ASEM)对视觉显示终端(VDT)用户干眼症(DED)的疗效。这项前瞻性随机临床试验包括具有干眼症相关特征的 VDT 用户,他们被随机分配到 ASEM 组(ASEM 2 周,20 人参加)或蒸汽温热眼罩(SEM)组(SEM 2 周,20 人参加)。收集治疗前后的泪膜破裂时间(TBUT)、施尔默试验、泪液半月板高度、眼表染色评分、眼睑和睑板腺检查、主观症状和生活质量(QoL)评分。采用广义线性混合模型比较两组患者症状和体征的改善情况。经过两周的治疗后,ASEM 组的所有主观症状和问卷评分均有明显改善(P 均小于 0.05),而 SEM 组的放松感、舒适感和清爽感均无变化(P 均大于 0.05)。ASEM 组的 TBUT、泪液半月板高度和下眼睑睑板腺质量明显优于 SEM 组(均 p <0.05),而 Schirmer 试验和眼表染色评分则无明显变化。与 SEM 组相比,ASEM 组的清爽感更强(p = 0.013),眼分泌物感更低(p = 0.031),TBUT 更高(p = 0.045),双眼皮的睑板腺表达能力更好(均 p < 0.05),双眼皮的睑板腺质量更好(均 p < 0.05),即使调整了年龄和性别也是如此。总之,与 SEM 相比,ASEM 可以改善 VDT 使用者的一些主观 DED 症状、泪膜稳定性和睑板腺状态。
{"title":"Effectiveness of an Acupuncture Steam-Warming Eye Mask on Dry Eye Disease in Visual Display Terminal Users: A Prospective Randomized Controlled Trial.","authors":"Chia-Yi Lee, Shun-Fa Yang, Ching-Hsi Hsiao, Chi-Chin Sun, Chao-Kai Chang, Jing-Yang Huang, Yih-Shiou Hwang","doi":"10.3390/diseases12080192","DOIUrl":"10.3390/diseases12080192","url":null,"abstract":"<p><p>We aim to evaluate the effectiveness of an acupuncture steam-warming eye mask (ASEM) on dry eye disease (DED) in visual display terminal (VDT) users. This prospective randomized clinical trial included VDT users with DED-related features who were randomly assigned to the ASEM group (ASEM for 2 weeks, 20 participants) or the steam-warming eye mask (SEM) group (SEM for 2 weeks, 20 participants). The tear film break-up time (TBUT), Schirmer test, tear meniscus height, ocular surface staining scores, eyelid and meibomian gland exam, subjective symptoms, and quality of life (QoL) scores before and after treatment were collected. A generalized linear mixed model was applied to compare the improvement of symptoms and signs between the two groups. After the 2-week treatment, all the subjective symptoms and questionnaire scores in the ASEM group improved significantly (all <i>p</i> < 0.05), whereas the feelings of relaxation, comfortable, and refreshment did not change in the SEM group (both <i>p</i> > 0.05). The TBUT, tear meniscus height, and meibum quality in the lower eyelid were significantly better in the ASEM group than the SEM group (all <i>p</i> < 0.05), whereas no significant changes were observed in the Schirmer test and ocular surface staining scores. Compared with the SEM group, the ASEM group experienced a stronger feeling of refreshment (<i>p</i> = 0.013), lower sensation of ocular discharge (<i>p</i> = 0.031), higher TBUT (<i>p</i> = 0.045), better meibomian gland expressibility of both eyelids (both <i>p</i> < 0.05), and better meibum quality of both eyelids (both <i>p</i> < 0.05), even after adjustments for age and sex. In conclusion, comparing with SEM, ASEM can improve some subjective DED symptoms, tear film stability, and meibum status in VDT users.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Ventricular Reverse Remodeling after Surgical Aortic Valve Replacement for Aortic Regurgitation-An Explorative Study. 主动脉瓣置换术治疗主动脉瓣反流后的左心室反向重塑--一项探索性研究。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-21 DOI: 10.3390/diseases12080191
Zsuzsanna Arnold, Alexander Elnekheli, Daniela Geisler, Thomas Aschacher, Verena Lenz, Bernhard Winkler, Reinhard Moidl, Martin Grabenwöger

Background: The timing of treatment for chronic aortic valve regurgitation (AR), especially in asymptomatic patients, is gaining attention since less invasive strategies have become available. The aim of the present study was to evaluate left ventricular reverse remodeling after aortic valve replacement (AVR) for severe AR.

Methods: Patients (n = 25) who underwent surgical AVR for severe AR with left ventricular ejection fraction (LVEF) less than 55% were included in this study. Preprocedural and follow-up clinical and echocardiographic measurements of LVEF and left ventricular (LV) diameters were retrospectively analyzed.

Results: Mean LVEF increased significantly following surgical AVR (p < 0.0001). LV diameters showed a clear regression (p = 0.0088). Younger patients and those receiving a mechanical valve tended to have less improved LVEF on follow-up than patients over 60 years or the ones who were implanted with a biological prosthesis (p = 0.0239 and p = 0.069, respectively). Gender had no effect on the degree of LVEF improvement (p = 0.4908).

Conclusions: We demonstrated significant LV reverse remodeling following AVR for AR. However, more data are needed on LV functional and geometrical improvement comparing the different types of valve prostheses to provide an optimal treatment strategy.

背景:慢性主动脉瓣反流(AR)的治疗时机,尤其是无症状患者的治疗时机,随着微创策略的出现而日益受到关注。本研究旨在评估主动脉瓣置换术(AVR)治疗严重主动脉瓣反流后左心室反向重塑的情况:本研究纳入了因左室射血分数(LVEF)小于 55% 的重度 AR 而接受手术 AVR 的患者(n = 25)。回顾性分析了手术前和随访期间 LVEF 和左心室(LV)直径的临床和超声心动图测量结果:结果:手术 AVR 后,平均 LVEF 明显增加(p < 0.0001)。左心室直径出现了明显的回归(p = 0.0088)。与 60 岁以上的患者或植入生物假体的患者相比,年轻患者和接受机械瓣膜的患者随访时 LVEF 的改善程度较低(分别为 p = 0.0239 和 p = 0.069)。性别对 LVEF 的改善程度没有影响(p = 0.4908):结论:我们证实了因 AR 而进行 AVR 后左心室逆向重塑的显著性。结论:我们的研究结果表明,AVR 术后左心室逆向重塑效果显著,但还需要更多关于左心室功能和几何改善的数据,并对不同类型的瓣膜假体进行比较,以提供最佳治疗策略。
{"title":"Left Ventricular Reverse Remodeling after Surgical Aortic Valve Replacement for Aortic Regurgitation-An Explorative Study.","authors":"Zsuzsanna Arnold, Alexander Elnekheli, Daniela Geisler, Thomas Aschacher, Verena Lenz, Bernhard Winkler, Reinhard Moidl, Martin Grabenwöger","doi":"10.3390/diseases12080191","DOIUrl":"10.3390/diseases12080191","url":null,"abstract":"<p><strong>Background: </strong>The timing of treatment for chronic aortic valve regurgitation (AR), especially in asymptomatic patients, is gaining attention since less invasive strategies have become available. The aim of the present study was to evaluate left ventricular reverse remodeling after aortic valve replacement (AVR) for severe AR.</p><p><strong>Methods: </strong>Patients (n = 25) who underwent surgical AVR for severe AR with left ventricular ejection fraction (LVEF) less than 55% were included in this study. Preprocedural and follow-up clinical and echocardiographic measurements of LVEF and left ventricular (LV) diameters were retrospectively analyzed.</p><p><strong>Results: </strong>Mean LVEF increased significantly following surgical AVR (<i>p</i> < 0.0001). LV diameters showed a clear regression (<i>p</i> = 0.0088). Younger patients and those receiving a mechanical valve tended to have less improved LVEF on follow-up than patients over 60 years or the ones who were implanted with a biological prosthesis (<i>p</i> = 0.0239 and <i>p</i> = 0.069, respectively). Gender had no effect on the degree of LVEF improvement (<i>p</i> = 0.4908).</p><p><strong>Conclusions: </strong>We demonstrated significant LV reverse remodeling following AVR for AR. However, more data are needed on LV functional and geometrical improvement comparing the different types of valve prostheses to provide an optimal treatment strategy.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Incidence of Clostridioides difficile Infection in the Post-COVID-19 Era in a Hospital in Northern Greece. 希腊北部一家医院在后 COVID-19 时代的艰难梭菌感染发病率。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-20 DOI: 10.3390/diseases12080190
Maria Terzaki, Dimitrios Kouroupis, Charalampos Zarras, Dimitrios Molyvas, Chrysi Michailidou, Panagiotis Pateinakis, Konstantina Mpani, Prodromos Soukiouroglou, Eleftheria Paida, Elisavet Simoulidou, Sofia Chatzimichailidou, Konstantinos Petidis, Athina Pyrpasopoulou

Clostridioides difficile infection (CDI) has evolved to be the most significant cause of healthcare-associated diarrhoea and one of the leading representatives of healthcare-associated infections, with a high associated mortality. The aim of this retrospective study was to record the incidence rates and the epidemiological and clinical features of CDI in a large tertiary hospital of northern Greece in the years 2022-2023. All patients with CDI-compatible symptomatology and a positive CDI diagnostic test (GDH-glutamate dehydrogenase and toxin-positive FIA-Fluorescent Immuno-chromatography-SD Biosensor, and/or film array) were included (104 from a total of 4560 admitted patients). Their demographic, laboratory, and clinical data were recorded and analysed. The incidence of CDI in admitted patients was found to be higher than previous reports in the geographical area, reaching 54.6/10,000 patient days and following a rising trend over the course of the study. Thirty-day mortality was high (39.4%), potentially related to new emerging hypervirulent C. difficile strains. In view of the high prevalence of multidrug-resistant organisms in the region, and the significant mortality associated with this infection, these findings particularly point to the need for the implementation of organized surveillance and infection prevention protocols.

艰难梭菌感染(CDI)已发展成为医疗相关性腹泻的最主要病因,也是医疗相关性感染的主要代表之一,相关死亡率很高。这项回顾性研究旨在记录 2022-2023 年希腊北部一家大型三甲医院的 CDI 发病率以及流行病学和临床特征。研究纳入了所有具有符合 CDI 症状且 CDI 诊断测试(GDH-谷氨酸脱氢酶和毒素阳性 FIA-荧光免疫层析-SD 生物传感器和/或薄膜阵列)呈阳性的患者(共 4560 名入院患者中的 104 名)。对他们的人口统计学、实验室和临床数据进行了记录和分析。研究发现,该地区入院患者的 CDI 发病率高于之前的报告,达到 54.6/10,000,并且在研究过程中呈上升趋势。三十天的死亡率很高(39.4%),这可能与新出现的高病毒艰难梭菌菌株有关。鉴于该地区耐多药生物的高流行率以及与这种感染相关的高死亡率,这些研究结果特别表明有必要实施有组织的监测和感染预防方案。
{"title":"The Incidence of <i>Clostridioides difficile</i> Infection in the Post-COVID-19 Era in a Hospital in Northern Greece.","authors":"Maria Terzaki, Dimitrios Kouroupis, Charalampos Zarras, Dimitrios Molyvas, Chrysi Michailidou, Panagiotis Pateinakis, Konstantina Mpani, Prodromos Soukiouroglou, Eleftheria Paida, Elisavet Simoulidou, Sofia Chatzimichailidou, Konstantinos Petidis, Athina Pyrpasopoulou","doi":"10.3390/diseases12080190","DOIUrl":"10.3390/diseases12080190","url":null,"abstract":"<p><p><i>Clostridioides difficile</i> infection (CDI) has evolved to be the most significant cause of healthcare-associated diarrhoea and one of the leading representatives of healthcare-associated infections, with a high associated mortality. The aim of this retrospective study was to record the incidence rates and the epidemiological and clinical features of CDI in a large tertiary hospital of northern Greece in the years 2022-2023. All patients with CDI-compatible symptomatology and a positive CDI diagnostic test (GDH-glutamate dehydrogenase and toxin-positive FIA-Fluorescent Immuno-chromatography-SD Biosensor, and/or film array) were included (104 from a total of 4560 admitted patients). Their demographic, laboratory, and clinical data were recorded and analysed. The incidence of CDI in admitted patients was found to be higher than previous reports in the geographical area, reaching 54.6/10,000 patient days and following a rising trend over the course of the study. Thirty-day mortality was high (39.4%), potentially related to new emerging hypervirulent <i>C. difficile</i> strains. In view of the high prevalence of multidrug-resistant organisms in the region, and the significant mortality associated with this infection, these findings particularly point to the need for the implementation of organized surveillance and infection prevention protocols.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Risk HPV Screening Initiative in Kosovo-A Way to Optimize HPV Vaccination for Cervical Cancer. 科索沃高危 HPV 筛查倡议--优化宫颈癌 HPV 疫苗接种的途径。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-19 DOI: 10.3390/diseases12080189
Jessica L Bentz, Rachael E Barney, Natalia Georgantzoglou, Suzana Manxhuka-Kerliu, Vlora Ademi Ibishi, Brikene Dacaj-Elshani, Suyapa Bejarano, Paul E Palumbo, Arvind Suresh, Ethan P M LaRochelle, William P Keegan, Teresa L Wilson, Betty J Dokus, Kenneth C Hershberger, Torrey L Gallagher, Samantha F Allen, Scott M Palisoul, Heather B Steinmetz, Linda S Kennedy, Gregory J Tsongalis

Nearly all cervical cancers are caused by persistent high-risk human papillomavirus (hrHPV) infection. There are 14 recognized hrHPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and hrHPV genotypes 16 and 18 comprise approximately 66% of all cases worldwide. An additional 15% of cervical cancers are caused by hrHPV genotypes 31, 33, 45, 52, and 58. Screening patients for hrHPV as a mechanism for implementation of early treatment is a proven strategy for decreasing the incidence of HPV-related neoplasia, cervical cancer in particular. Here, we present population data from an HPV screening initiative in Kosovo designed to better understand the prevalence of the country's HPV burden and local incidence of cervical cancer by hrHPV genotype. Nearly 2000 women were screened for hrHPV using a real-time polymerase chain reaction (real-time PCR) assay followed by melt curve analysis to establish the prevalence of hrHPV in Kosovo. Additionally, DNA was extracted from 200 formalin-fixed, paraffin embedded cervical tumors and tested for hrHPV using the same method. Cervical screening samples revealed a high prevalence of hrHPV genotypes 16 and 51, while cervical cancer specimens predominantly harbored genotypes 16, 18, and 45. This is the first comprehensive screening study for evaluating the prevalence of hrHPV genotypes in Kosovo on screening cervical brush samples and cervical neoplasms. Given the geographic distribution of hrHPV genotypes and the WHO's global initiative to eliminate cervical cancer, this study can support and direct vaccination efforts to cover highly prevalent hrHPV genotypes in Kosovo's at-risk population.

几乎所有的宫颈癌都是由持续的高危人乳头瘤病毒(hrHPV)感染引起的。目前公认的 hrHPV 基因型有 14 种(HPV 16、18、31、33、35、39、45、51、52、56、58、59、66 和 68),其中 hrHPV 基因型 16 和 18 约占全球病例总数的 66%。另有 15%的宫颈癌是由 hrHPV 基因型 31、33、45、52 和 58 引起的。对患者进行 hrHPV 筛查作为早期治疗的一种机制,是降低 HPV 相关肿瘤(尤其是宫颈癌)发病率的一种行之有效的策略。在此,我们介绍了科索沃 HPV 筛查计划的人群数据,该计划旨在更好地了解该国的 HPV 感染情况以及当地按 hrHPV 基因型划分的宫颈癌发病率。使用实时聚合酶链式反应(real-time PCR)检测法对近 2000 名妇女进行了 hrHPV 筛查,然后进行熔融曲线分析,以确定 hrHPV 在科索沃的流行率。此外,还从 200 个经福尔马林固定、石蜡包埋的宫颈肿瘤中提取了 DNA,并用同样的方法对其进行了 hrHPV 检测。宫颈筛查样本显示 hrHPV 基因型 16 和 51 的高流行率,而宫颈癌标本主要携带基因型 16、18 和 45。这是科索沃首次对宫颈刷筛查样本和宫颈癌标本的 hrHPV 基因型流行率进行评估的全面筛查研究。考虑到 hrHPV 基因型的地理分布和世界卫生组织消除宫颈癌的全球倡议,这项研究可以支持和指导疫苗接种工作,以覆盖科索沃高危人群中高发的 hrHPV 基因型。
{"title":"High-Risk HPV Screening Initiative in Kosovo-A Way to Optimize HPV Vaccination for Cervical Cancer.","authors":"Jessica L Bentz, Rachael E Barney, Natalia Georgantzoglou, Suzana Manxhuka-Kerliu, Vlora Ademi Ibishi, Brikene Dacaj-Elshani, Suyapa Bejarano, Paul E Palumbo, Arvind Suresh, Ethan P M LaRochelle, William P Keegan, Teresa L Wilson, Betty J Dokus, Kenneth C Hershberger, Torrey L Gallagher, Samantha F Allen, Scott M Palisoul, Heather B Steinmetz, Linda S Kennedy, Gregory J Tsongalis","doi":"10.3390/diseases12080189","DOIUrl":"10.3390/diseases12080189","url":null,"abstract":"<p><p>Nearly all cervical cancers are caused by persistent high-risk human papillomavirus (hrHPV) infection. There are 14 recognized hrHPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and hrHPV genotypes 16 and 18 comprise approximately 66% of all cases worldwide. An additional 15% of cervical cancers are caused by hrHPV genotypes 31, 33, 45, 52, and 58. Screening patients for hrHPV as a mechanism for implementation of early treatment is a proven strategy for decreasing the incidence of HPV-related neoplasia, cervical cancer in particular. Here, we present population data from an HPV screening initiative in Kosovo designed to better understand the prevalence of the country's HPV burden and local incidence of cervical cancer by hrHPV genotype. Nearly 2000 women were screened for hrHPV using a real-time polymerase chain reaction (real-time PCR) assay followed by melt curve analysis to establish the prevalence of hrHPV in Kosovo. Additionally, DNA was extracted from 200 formalin-fixed, paraffin embedded cervical tumors and tested for hrHPV using the same method. Cervical screening samples revealed a high prevalence of hrHPV genotypes 16 and 51, while cervical cancer specimens predominantly harbored genotypes 16, 18, and 45. This is the first comprehensive screening study for evaluating the prevalence of hrHPV genotypes in Kosovo on screening cervical brush samples and cervical neoplasms. Given the geographic distribution of hrHPV genotypes and the WHO's global initiative to eliminate cervical cancer, this study can support and direct vaccination efforts to cover highly prevalent hrHPV genotypes in Kosovo's at-risk population.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Feasibility of Prenatal Ultrasonic Screening for Developmental Dysplasia of the Hip. 产前超声波筛查髋关节发育不良的可行性。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-17 DOI: 10.3390/diseases12080188
Claudia Bevilacqua, Virginia Boscarato, Giovanni Pieroni, Eva Fraternali, Giuliano Lattanzi, Simone Domenico Aspriello, Antonio Pompilio Gigante, Alessandro Cecchi

Background: developmental dysplasia of the hip (DDH) is a condition characterized by abnormal hip development in infancy. Early diagnosis allows for effective treatment, while late presentation often necessitates complex surgical interventions. Current recommendations advise screening between the 6th and 8th week postnatal using an ultrasound, typically employing the Graf method. However, there is no universal consensus on whether ultrasound screening significantly increases treatment likelihood compared to clinical examination-guided ultrasound. This study aims to explore the feasibility of prenatal ultrasound for the early identification of DDH risk.

Methods: This prospective observational study involved 100 pregnant women undergoing fetal hip ultrasounds during the second and third trimesters. Using the modified Graf method, alpha and beta angles were calculated on the fetus. Postnatally, alpha and beta angles were compared with the prenatal values.

Results: Prenatal ultrasound at the 24th week showed inconclusive results because of the difficulty in identification of Graf landmarks, while ultrasound at the 34th week proved to be a reliable and safe method for the quantitative determination of alpha and beta angles. Significant correlations were found between prenatal and postnatal alpha and beta angles. Moreover, significant differences in prenatal alpha and beta values were observed in patients developing mature/immature hips postnatally.

Conclusions: Prenatal diagnostics show promise for predicting infant hip development. Further research is warranted to validate correlation strength and clinical applicability.

背景:髋关节发育不良(DDH)是一种以婴儿期髋关节发育异常为特征的疾病。早期诊断可进行有效治疗,而晚期往往需要进行复杂的手术干预。目前的建议是在产后第 6 到第 8 周进行超声波筛查,通常采用格拉夫法。然而,与临床检查引导下的超声波检查相比,超声波筛查是否能显著提高治疗的可能性,目前尚未达成普遍共识。本研究旨在探讨产前超声检查早期识别 DDH 风险的可行性:这项前瞻性观察研究涉及 100 名在第二和第三个孕期接受胎儿髋部超声检查的孕妇。采用改良格拉夫法计算胎儿的α角和β角。产后,将α角和β角与产前值进行比较:结果:由于难以识别格拉夫地标,第 24 周的产前超声检查结果并不确定,而第 34 周的超声检查被证明是定量测定α角和β角的可靠而安全的方法。产前和产后α角和β角之间存在显著的相关性。此外,在产后发育成熟/不成熟髋关节的患者中观察到产前α和β值的明显差异:结论:产前诊断显示了预测婴儿髋关节发育的前景。结论:产前诊断有望预测婴儿的髋关节发育,但还需要进一步的研究来验证相关性和临床适用性。
{"title":"The Feasibility of Prenatal Ultrasonic Screening for Developmental Dysplasia of the Hip.","authors":"Claudia Bevilacqua, Virginia Boscarato, Giovanni Pieroni, Eva Fraternali, Giuliano Lattanzi, Simone Domenico Aspriello, Antonio Pompilio Gigante, Alessandro Cecchi","doi":"10.3390/diseases12080188","DOIUrl":"10.3390/diseases12080188","url":null,"abstract":"<p><strong>Background: </strong>developmental dysplasia of the hip (DDH) is a condition characterized by abnormal hip development in infancy. Early diagnosis allows for effective treatment, while late presentation often necessitates complex surgical interventions. Current recommendations advise screening between the 6th and 8th week postnatal using an ultrasound, typically employing the Graf method. However, there is no universal consensus on whether ultrasound screening significantly increases treatment likelihood compared to clinical examination-guided ultrasound. This study aims to explore the feasibility of prenatal ultrasound for the early identification of DDH risk.</p><p><strong>Methods: </strong>This prospective observational study involved 100 pregnant women undergoing fetal hip ultrasounds during the second and third trimesters. Using the modified Graf method, alpha and beta angles were calculated on the fetus. Postnatally, alpha and beta angles were compared with the prenatal values.</p><p><strong>Results: </strong>Prenatal ultrasound at the 24th week showed inconclusive results because of the difficulty in identification of Graf landmarks, while ultrasound at the 34th week proved to be a reliable and safe method for the quantitative determination of alpha and beta angles. Significant correlations were found between prenatal and postnatal alpha and beta angles. Moreover, significant differences in prenatal alpha and beta values were observed in patients developing mature/immature hips postnatally.</p><p><strong>Conclusions: </strong>Prenatal diagnostics show promise for predicting infant hip development. Further research is warranted to validate correlation strength and clinical applicability.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Glycosylated Hemoglobin Levels and Vaccine Preventable Diseases: A Systematic Review. 糖化血红蛋白水平与疫苗可预防疾病之间的关系:系统回顾。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-17 DOI: 10.3390/diseases12080187
Elda De Vita, Federica Limongi, Nicola Veronese, Francesco Di Gennaro, Annalisa Saracino, Stefania Maggi

People with diabetes are at higher risk of serious complications from many vaccine-preventable diseases (VPDs). Some studies have highlighted the potential impact of glycosylated hemoglobin levels (HbA1c), but no systematic review has synthesized these findings. Of the 823 identified studies, 3 were included, for a total of 705,349 participants. Regarding the incidence of herpes zoster (HZ), one study found that higher HbA1c levels at the baseline (>10.3%) were associated with a significantly higher risk of HZ of 44%, compared to those with a good HbA1c control (6.7%). On the contrary, the second one reported that when compared to the reference group (HbA1c of 5.0-6.4%), participants with a HbA1c less than 5.0% were at higher risk of HZ of 63%, whilst participants with a HBA1c more than 9.5% had a similar risk. Finally, the third study observed that diabetes, defined using a value of HbA1c more than 7.5%, was associated with an increased risk of mortality in men with COVID-19. In conclusion, both high and low HBA1c levels appear to be associated with a higher risk of HZ. Regarding COVID-19, a value of HbA1c more than 7.5% was associated with a higher risk of death in COVID-19, but only in men.

糖尿病患者患许多疫苗可预防疾病 (VPD) 的严重并发症的风险更高。一些研究强调了糖化血红蛋白水平(HbA1c)的潜在影响,但还没有系统性综述对这些研究结果进行归纳。在已确定的 823 项研究中,有 3 项被纳入,共有 705349 名参与者。关于带状疱疹(HZ)的发病率,一项研究发现,与 HbA1c 控制良好者(6.7%)相比,基线 HbA1c 水平较高者(>10.3%)患 HZ 的风险显著增加 44%。相反,第二项研究报告称,与参照组(HbA1c 为 5.0-6.4%)相比,HbA1c 低于 5.0% 的参与者罹患 HZ 的风险高出 63%,而 HBA1c 高于 9.5% 的参与者罹患 HZ 的风险与参照组相似。最后,第三项研究发现,HbA1c 值超过 7.5% 的糖尿病与 COVID-19 男性患者的死亡风险增加有关。总之,HBA1c 水平过高和过低似乎都与罹患 HZ 的风险较高有关。至于 COVID-19,HbA1c 值超过 7.5%与 COVID-19 中较高的死亡风险有关,但仅限于男性。
{"title":"Association between Glycosylated Hemoglobin Levels and Vaccine Preventable Diseases: A Systematic Review.","authors":"Elda De Vita, Federica Limongi, Nicola Veronese, Francesco Di Gennaro, Annalisa Saracino, Stefania Maggi","doi":"10.3390/diseases12080187","DOIUrl":"10.3390/diseases12080187","url":null,"abstract":"<p><p>People with diabetes are at higher risk of serious complications from many vaccine-preventable diseases (VPDs). Some studies have highlighted the potential impact of glycosylated hemoglobin levels (HbA1c), but no systematic review has synthesized these findings. Of the 823 identified studies, 3 were included, for a total of 705,349 participants. Regarding the incidence of herpes zoster (HZ), one study found that higher HbA1c levels at the baseline (>10.3%) were associated with a significantly higher risk of HZ of 44%, compared to those with a good HbA1c control (6.7%). On the contrary, the second one reported that when compared to the reference group (HbA1c of 5.0-6.4%), participants with a HbA1c less than 5.0% were at higher risk of HZ of 63%, whilst participants with a HBA1c more than 9.5% had a similar risk. Finally, the third study observed that diabetes, defined using a value of HbA1c more than 7.5%, was associated with an increased risk of mortality in men with COVID-19. In conclusion, both high and low HBA1c levels appear to be associated with a higher risk of HZ. Regarding COVID-19, a value of HbA1c more than 7.5% was associated with a higher risk of death in COVID-19, but only in men.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial. 塞马鲁肽对伴有 2 型糖尿病和肥胖症的非酒精性脂肪肝的治疗效果:一项开放标签对照试验
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-17 DOI: 10.3390/diseases12080186
Ahmed I Gad, Nevin F Ibrahim, Noura Almadani, Rasha Mahfouz, Hanaa A Nofal, Dina S El-Rafey, Hossam Tharwat Ali, Amr T El-Hawary, Ayman M E M Sadek

Background: GLP-1 receptor agonists (GLP-1 RAs) have been shown to improve glycemic control and insulin sensitivity and reduce body weight in obese patients with type 2 diabetes mellitus (T2D). This trial sought to evaluate the therapeutic effect of oral and subcutaneous semaglutide in NAFLD and its sequelae in obesity and/or T2D.

Methods: In an open-labelled intervention study, the sample was 180 patients classified into three parallel groups (1:1:1): group I received oral semaglutide, group II patients received injectable semaglutide, and group III received pioglitazone and/or vitamin E. Patients were evaluated at 6 and 12 months.

Results: There was a substantial improvement in lipid profile, liver enzymes, and body mass index, especially in group II. As for HDL, only group II showed a consistent increase at both 6 months (51 ± 4.62 mg/dL) and 12 months (50.08 ± 2.45 mg/dL) compared with baseline (45.6 ± 6.37 mg/dL) (p-value < 0.001). Despite the non-significant difference in NAFLD fibrosis score (NFS) (p-value = 0.45 and 0.63), group II had significantly lower scores of the fibrosis-4 score (FIB-4), liver stiffness measurement (LSM), and controlled attenuation parameter (CAP) at 6 and 12 months (p-value < 0.001). Conclusions: Semaglutide improves lipid profile, liver steatosis, and fibrosis parameters and reduces the BMI in T2D and obese patients with NAFLD.

背景:GLP-1受体激动剂(GLP-1 RAs)已被证明可改善2型糖尿病(T2D)肥胖患者的血糖控制和胰岛素敏感性,并减轻体重。本试验旨在评估口服和皮下注射塞马鲁肽对肥胖和/或T2D患者非酒精性脂肪肝及其后遗症的治疗效果:在一项开放标签干预研究中,样本为180名患者,分为三个平行组(1:1:1):I组患者接受口服塞马鲁肽,II组患者接受注射塞马鲁肽,III组患者接受吡格列酮和/或维生素E:结果:血脂、肝酶和体重指数均有显著改善,尤其是第二组。至于高密度脂蛋白,与基线值(45.6 ± 6.37 mg/dL)相比,只有第二组在 6 个月(51 ± 4.62 mg/dL)和 12 个月(50.08 ± 2.45 mg/dL)时显示出持续增长(P 值 < 0.001)。尽管非酒精性脂肪肝纤维化评分(NFS)差异不显著(p 值 = 0.45 和 0.63),但在 6 个月和 12 个月时,II 组的纤维化-4 评分(FIB-4)、肝脏僵硬度测量(LSM)和受控衰减参数(CAP)得分显著降低(p 值 < 0.001)。结论塞马鲁肽可改善患有非酒精性脂肪肝的T2D和肥胖患者的血脂概况、肝脏脂肪变性和纤维化参数,并降低体重指数。
{"title":"Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.","authors":"Ahmed I Gad, Nevin F Ibrahim, Noura Almadani, Rasha Mahfouz, Hanaa A Nofal, Dina S El-Rafey, Hossam Tharwat Ali, Amr T El-Hawary, Ayman M E M Sadek","doi":"10.3390/diseases12080186","DOIUrl":"10.3390/diseases12080186","url":null,"abstract":"<p><strong>Background: </strong>GLP-1 receptor agonists (GLP-1 RAs) have been shown to improve glycemic control and insulin sensitivity and reduce body weight in obese patients with type 2 diabetes mellitus (T2D). This trial sought to evaluate the therapeutic effect of oral and subcutaneous semaglutide in NAFLD and its sequelae in obesity and/or T2D.</p><p><strong>Methods: </strong>In an open-labelled intervention study, the sample was 180 patients classified into three parallel groups (1:1:1): group I received oral semaglutide, group II patients received injectable semaglutide, and group III received pioglitazone and/or vitamin E. Patients were evaluated at 6 and 12 months.</p><p><strong>Results: </strong>There was a substantial improvement in lipid profile, liver enzymes, and body mass index, especially in group II. As for HDL, only group II showed a consistent increase at both 6 months (51 ± 4.62 mg/dL) and 12 months (50.08 ± 2.45 mg/dL) compared with baseline (45.6 ± 6.37 mg/dL) (<i>p</i>-value < 0.001). Despite the non-significant difference in NAFLD fibrosis score (NFS) (<i>p</i>-value = 0.45 and 0.63), group II had significantly lower scores of the fibrosis-4 score (FIB-4), liver stiffness measurement (LSM), and controlled attenuation parameter (CAP) at 6 and 12 months (<i>p</i>-value < 0.001). <b>Conclusions:</b> Semaglutide improves lipid profile, liver steatosis, and fibrosis parameters and reduces the BMI in T2D and obese patients with NAFLD.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indole-3 Carbinol and Diindolylmethane Mitigated β-Amyloid-Induced Neurotoxicity and Acetylcholinesterase Enzyme Activity: In Silico, In Vitro, and Network Pharmacology Study. 吲哚-3-甲醇和二吲哚甲烷减轻了β-淀粉样蛋白诱导的神经毒性和乙酰胆碱酯酶活性:硅学、体外和网络药理学研究。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-16 DOI: 10.3390/diseases12080184
Kakarla Ramakrishna, Praditha Karuturi, Queen Siakabinga, Gajendra T A, Sairam Krishnamurthy, Shreya Singh, Sonia Kumari, G Siva Kumar, M Elizabeth Sobhia, Sachchida Nand Rai

Background: Alzheimer's disease (AD) is a neurodegenerative disease characterized by beta-amyloid (Aβ) deposition and increased acetylcholinesterase (AchE) enzyme activities. Indole 3 carbinol (I3C) and diindolylmethane (DIM) are reported to have neuroprotective activities against various neurological diseases, including ischemic stroke, Parkinson's disease, neonatal asphyxia, depression, stress, neuroinflammation, and excitotoxicity, except for AD. In the present study, we have investigated the anti-AD effects of I3C and DIM. Methods: Docking and molecular dynamic studies against AchE enzyme and network pharmacological studies were conducted for I3C and DIM. I3C and DIM's neuroprotective effects against self and AchE-induced Aβ aggregation were investigated. The neuroprotective effects of I3C and DIM against Aβ-induced neurotoxicity were assessed in SH-S5Y5 cells by observing cell viability and ROS. Results: Docking studies against AchE enzyme with I3C and DIM show binding efficiency of -7.0 and -10.3, respectively, and molecular dynamics studies revealed a better interaction and stability between I3C and AchE and DIM and AchE. Network pharmacological studies indicated that I3C and DIM interacted with several proteins involved in the pathophysiology of AD. Further, I3C and DIM significantly inhibited the AchE (IC50: I3C (18.98 µM) and DIM (11.84 µM)) and self-induced Aβ aggregation. Both compounds enhanced the viability of SH-S5Y5 cells that are exposed to Aβ and reduced ROS. Further, I3C and DIM show equipotential neuroprotection when compared to donepezil. Conclusions: Our findings indicate that both I3C and DIM show anti-AD effects by inhibiting the Aβ induced neurotoxicity and AchE activities.

背景:阿尔茨海默病(AD)是一种以β-淀粉样蛋白(Aβ)沉积和乙酰胆碱酯酶(AchE)活性增加为特征的神经退行性疾病。据报道,吲哚-3-甲醇(I3C)和二吲哚甲烷(DIM)对多种神经系统疾病具有神经保护活性,包括缺血性中风、帕金森病、新生儿窒息、抑郁、应激、神经炎症和兴奋毒性,但 AD 除外。本研究探讨了 I3C 和 DIM 的抗 AD 作用。研究方法对 I3C 和 DIM 进行了针对 AchE 酶的对接和分子动力学研究以及网络药理学研究。研究了 I3C 和 DIM 对自身和 AchE 诱导的 Aβ 聚集的神经保护作用。通过观察 SH-S5Y5 细胞的活力和 ROS,评估了 I3C 和 DIM 对 Aβ 诱导的神经毒性的神经保护作用。结果I3C和DIM与AchE酶的对接研究表明,它们的结合效率分别为-7.0和-10.3,分子动力学研究表明,I3C与AchE和DIM与AchE之间有更好的相互作用和稳定性。网络药理学研究表明,I3C 和 DIM 与多种参与艾滋病病理生理学的蛋白质相互作用。此外,I3C 和 DIM 还能显著抑制 AchE(IC50:I3C(18.98 µM)和 DIM(11.84 µM))和自身诱导的 Aβ 聚集。这两种化合物都能提高暴露于 Aβ 的 SH-S5Y5 细胞的活力,并减少 ROS。此外,与多奈哌齐相比,I3C 和 DIM 显示出同等的神经保护作用。结论:我们的研究结果表明,I3C 和 DIM 都能抑制 Aβ 诱导的神经毒性和 AchE 活性,从而显示出抗 AD 的作用。
{"title":"Indole-3 Carbinol and Diindolylmethane Mitigated β-Amyloid-Induced Neurotoxicity and Acetylcholinesterase Enzyme Activity: In Silico, In Vitro, and Network Pharmacology Study.","authors":"Kakarla Ramakrishna, Praditha Karuturi, Queen Siakabinga, Gajendra T A, Sairam Krishnamurthy, Shreya Singh, Sonia Kumari, G Siva Kumar, M Elizabeth Sobhia, Sachchida Nand Rai","doi":"10.3390/diseases12080184","DOIUrl":"10.3390/diseases12080184","url":null,"abstract":"<p><p><b>Background:</b> Alzheimer's disease (AD) is a neurodegenerative disease characterized by beta-amyloid (Aβ) deposition and increased acetylcholinesterase (AchE) enzyme activities. Indole 3 carbinol (I3C) and diindolylmethane (DIM) are reported to have neuroprotective activities against various neurological diseases, including ischemic stroke, Parkinson's disease, neonatal asphyxia, depression, stress, neuroinflammation, and excitotoxicity, except for AD. In the present study, we have investigated the anti-AD effects of I3C and DIM. <b>Methods:</b> Docking and molecular dynamic studies against AchE enzyme and network pharmacological studies were conducted for I3C and DIM. I3C and DIM's neuroprotective effects against self and AchE-induced Aβ aggregation were investigated. The neuroprotective effects of I3C and DIM against Aβ-induced neurotoxicity were assessed in SH-S5Y5 cells by observing cell viability and ROS. <b>Results:</b> Docking studies against AchE enzyme with I3C and DIM show binding efficiency of -7.0 and -10.3, respectively, and molecular dynamics studies revealed a better interaction and stability between I3C and AchE and DIM and AchE. Network pharmacological studies indicated that I3C and DIM interacted with several proteins involved in the pathophysiology of AD. Further, I3C and DIM significantly inhibited the AchE (IC<sub>50</sub>: I3C (18.98 µM) and DIM (11.84 µM)) and self-induced Aβ aggregation. Both compounds enhanced the viability of SH-S5Y5 cells that are exposed to Aβ and reduced ROS. Further, I3C and DIM show equipotential neuroprotection when compared to donepezil. <b>Conclusions:</b> Our findings indicate that both I3C and DIM show anti-AD effects by inhibiting the Aβ induced neurotoxicity and AchE activities.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-Driven Patient Education in Chronic Kidney Disease: Evaluating Chatbot Responses against Clinical Guidelines. 人工智能驱动的慢性肾病患者教育:根据临床指南评估聊天机器人的响应。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-16 DOI: 10.3390/diseases12080185
Prakrati C Acharya, Raul Alba, Pajaree Krisanapan, Chirag M Acharya, Supawadee Suppadungsuk, Eva Csongradi, Michael A Mao, Iasmina M Craici, Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn

Chronic kidney disease (CKD) patients can benefit from personalized education on lifestyle and nutrition management strategies to enhance healthcare outcomes. The potential use of chatbots, introduced in 2022, as a tool for educating CKD patients has been explored. A set of 15 questions on lifestyle modification and nutrition, derived from a thorough review of three specific KDIGO guidelines, were developed and posed in various formats, including original, paraphrased with different adverbs, incomplete sentences, and misspellings. Four versions of AI were used to answer these questions: ChatGPT 3.5 (March and September 2023 versions), ChatGPT 4, and Bard AI. Additionally, 20 questions on lifestyle modification and nutrition were derived from the NKF KDOQI guidelines for nutrition in CKD (2020 Update) and answered by four versions of chatbots. Nephrologists reviewed all answers for accuracy. ChatGPT 3.5 produced largely accurate responses across the different question complexities, with occasional misleading statements from the March version. The September 2023 version frequently cited its last update as September 2021 and did not provide specific references, while the November 2023 version did not provide any misleading information. ChatGPT 4 presented answers similar to 3.5 but with improved reference citations, though not always directly relevant. Bard AI, while largely accurate with pictorial representation at times, occasionally produced misleading statements and had inconsistent reference quality, although an improvement was noted over time. Bing AI from November 2023 had short answers without detailed elaboration and sometimes just answered "YES". Chatbots demonstrate potential as personalized educational tools for CKD that utilize layman's terms, deliver timely and rapid responses in multiple languages, and offer a conversational pattern advantageous for patient engagement. Despite improvements observed from March to November 2023, some answers remained potentially misleading. ChatGPT 4 offers some advantages over 3.5, although the differences are limited. Collaboration between healthcare professionals and AI developers is essential to improve healthcare delivery and ensure the safe incorporation of chatbots into patient care.

慢性肾脏病(CKD)患者可以从有关生活方式和营养管理策略的个性化教育中获益,从而提高医疗效果。我们对 2022 年推出的聊天机器人作为教育 CKD 患者的工具的潜在用途进行了探索。通过对三份特定的 KDIGO 指南进行全面审查,我们开发了一套关于生活方式调整和营养的 15 个问题,并以不同的形式提出,包括原文、使用不同副词的转述、不完整的句子和拼写错误。回答这些问题使用了四个版本的人工智能:ChatGPT 3.5(2023 年 3 月版和 9 月版)、ChatGPT 4 和 Bard AI。此外,20 个关于生活方式调整和营养的问题来自 NKF KDOQI CKD 营养指南(2020 年更新版),由四个版本的聊天机器人回答。肾病专家审查了所有答案的准确性。ChatGPT 3.5 在不同的问题复杂度上都做出了基本准确的回答,3 月份的版本偶尔会出现误导性陈述。2023 年 9 月版经常提到其最后更新时间为 2021 年 9 月,但没有提供具体参考信息,而 2023 年 11 月版则没有提供任何误导性信息。ChatGPT 4 提供的答案与 3.5 类似,但改进了参考引用,尽管并非总是直接相关。Bard AI 虽然在很大程度上是准确的,有时还提供了图片展示,但偶尔会出现误导性陈述,参考文献质量也不一致,不过随着时间的推移,情况有所改善。2023 年 11 月的必应人工智能回答简短,没有详细说明,有时只回答 "是"。聊天机器人利用通俗易懂的术语,以多种语言提供及时、快速的回复,并提供有利于患者参与的对话模式,显示出作为 CKD 个性化教育工具的潜力。尽管从 2023 年 3 月到 11 月观察到的情况有所改善,但一些答案仍可能具有误导性。ChatGPT 4 与 3.5 相比具有一些优势,但差异有限。医疗保健专业人员和人工智能开发人员之间的合作对于改善医疗服务和确保聊天机器人安全地融入患者护理至关重要。
{"title":"AI-Driven Patient Education in Chronic Kidney Disease: Evaluating Chatbot Responses against Clinical Guidelines.","authors":"Prakrati C Acharya, Raul Alba, Pajaree Krisanapan, Chirag M Acharya, Supawadee Suppadungsuk, Eva Csongradi, Michael A Mao, Iasmina M Craici, Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn","doi":"10.3390/diseases12080185","DOIUrl":"10.3390/diseases12080185","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) patients can benefit from personalized education on lifestyle and nutrition management strategies to enhance healthcare outcomes. The potential use of chatbots, introduced in 2022, as a tool for educating CKD patients has been explored. A set of 15 questions on lifestyle modification and nutrition, derived from a thorough review of three specific KDIGO guidelines, were developed and posed in various formats, including original, paraphrased with different adverbs, incomplete sentences, and misspellings. Four versions of AI were used to answer these questions: ChatGPT 3.5 (March and September 2023 versions), ChatGPT 4, and Bard AI. Additionally, 20 questions on lifestyle modification and nutrition were derived from the NKF KDOQI guidelines for nutrition in CKD (2020 Update) and answered by four versions of chatbots. Nephrologists reviewed all answers for accuracy. ChatGPT 3.5 produced largely accurate responses across the different question complexities, with occasional misleading statements from the March version. The September 2023 version frequently cited its last update as September 2021 and did not provide specific references, while the November 2023 version did not provide any misleading information. ChatGPT 4 presented answers similar to 3.5 but with improved reference citations, though not always directly relevant. Bard AI, while largely accurate with pictorial representation at times, occasionally produced misleading statements and had inconsistent reference quality, although an improvement was noted over time. Bing AI from November 2023 had short answers without detailed elaboration and sometimes just answered \"YES\". Chatbots demonstrate potential as personalized educational tools for CKD that utilize layman's terms, deliver timely and rapid responses in multiple languages, and offer a conversational pattern advantageous for patient engagement. Despite improvements observed from March to November 2023, some answers remained potentially misleading. ChatGPT 4 offers some advantages over 3.5, although the differences are limited. Collaboration between healthcare professionals and AI developers is essential to improve healthcare delivery and ensure the safe incorporation of chatbots into patient care.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Diseases (Basel, Switzerland)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1